Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient

Hepatology

Volumn 47, Issue 2, 2008, Pages 766-767

  Colson, Philippe ^a,b   Brouk, Nabil ^a,b   Lembo, Frédérique ^a,b   Castellani, Paul ^c   Tamalet, Catherine ^a,b   Gérolami, René ^d  

^a TIMONE HOSPITAL   (France)

^b CNRS   (France)

^c HÔPITAL SAINT JOSEPH   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 3; PROTEINASE; PROTEINASE INHIBITOR; TELAPREVIR;

ADULT; AMINO ACID SUBSTITUTION; CASE REPORT; CHRONIC HEPATITIS; DRUG RESISTANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMINO ACID SUBSTITUTION; DNA PRIMERS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 39549123821     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22122     Document Type: Letter

References (7)

1. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. HEPATOLOGY 2007;46:631-639.
2. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. HEPATOLOGY 2007;46:640-648.
3. Colson P, Tamalet C, Raoult D. SVARAP and aSVARAP: simple tools for quantitative analysis of nucleotide and amino acid variability and primer selection for clinical microbiology. BMC Microbiol 2006;6:21.
4. Henry M, Tourres C, Colson P, Ravaux I, Poizot-Martin I, Tamalet C. Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome. J Clin Virol 2006;37:227-230.
5. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777.
6. Zhou Y, Muh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and inrerferon alpha. J Biol Chem 2007;282:22619-22628.
7. Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, et al. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr 2007;46:174-180.